Intervencionista
Un ensayo clínico en el que se usa un nuevo medicamento o dispositivo para medir un resultado específico.
AMPLITUDE
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 12 Years and Older With APOL1-mediated Proteinuric Kidney Disease
The purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of VX-147 in participants aged 12 years and older with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.
Intervencionista
Un ensayo clínico en el que se usa un nuevo medicamento o dispositivo para medir un resultado específico.
AMPLITUDE
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 12 Years and Older With APOL1-mediated Proteinuric Kidney Disease
The purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of VX-147 in participants aged 12 years and older with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.
Criterios de elegibilidad
Población de pacientes
Key Inclusion Criteria:
• APOL1 genotype assessed during screening, participants must have of G1/G1, G2/G2, or G1/G2
• Proteinuric(protein in the urine) kidney disease
Key Exclusion Criteria:
• History of diabetes mellitus(type 1 or type 2)
• Uncontrolled hypertension
• Solid organ or bone marrow transplant
• Known underlying cause of kidney disease including but not limited to sickle cell disease
Other protocol defined Inclusion/Exclusion criteria apply.
Edad
18 — 26+
¿Pueden los pacientes con trasplante de riñón calificar para este ensayo?
No
¿Los pacientes que se encuentran actualmente en diálisis pueden calificar para este ensayo?
No
TFGe
15 a 29 — > 60
UPCR
1,1 a 2,0 — 3,0 o más
¿Qué tratamientos pueden haber tomado los pacientes para calificar para este ensayo?
Inhibidores ACE/ARB, Prednisona (Esteroides)
¿Qué tipo de pacientes de las categorías siguientes pueden participar?
Resistente al tratamiento, Dependiente de esteroides
Sobre el medicamento o la intervención
Qué implica para el paciente
Nombre del patrocinador
Vertex
Fecha estimada de finalización
2027
Sobre el estudio
Nombre del fármaco del estudio
VX-147-301
Sobre el medicamento o la intervención
The AMPLITUDE clinical research study is exploring an investigational study drug called VX-147 to learn more about how well it works as a treatment for people living with APOL1-mediated kidney disease. VX-147 has been tested in other studies with healthy volunteers and other people with a similar type of kidney disease.